This study tests whether adding eftilagimod alfa to standard immunotherapy and chemotherapy helps people with advanced non-small cell lung cancer live longer or keep their cancer from growing. About 756 adults who have not had prior treatment for their advanced disease will recei…
Phase: PHASE3 • Sponsor: Immutep S.A.S. • Aim: Disease control
Last updated Apr 24, 2026 16:19 UTC